Comparative Pharmacology
Head-to-head clinical analysis: 8 MOP versus TRISORALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: 8 MOP versus TRISORALEN.
8-MOP vs TRISORALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
8-MOP (methoxsalen) is a psoralen compound that intercalates into DNA. Upon UVA irradiation, it forms covalent cross-links between pyrimidine bases, inhibiting DNA synthesis and cell division. It also reduces the proliferation of epidermal cells and suppresses cutaneous immune responses by inhibiting antigen presentation and cytokine release.
Psoralen (trisoralen) intercalates into DNA and, upon UVA irradiation, forms covalent cross-links between pyrimidine bases, inhibiting DNA replication and cell division. It also suppresses DNA synthesis and epidermal cell proliferation.
Psoriasis: 0.4–0.6 mg/kg orally 2 hours before UVA exposure, 2–3 times per week. Vitiligo: 20 mg (0.3–0.4 mg/kg) 2 hours before UVA. Dose adjusted based on skin type and UVA dose.
10-70 mg orally 2 hours before UVA exposure, given 2-3 times per week, with dose based on body weight (0.6 mg/kg).
None Documented
None Documented
Terminal elimination half-life is 1–2 hours; however, clinical effect persists longer due to sustained phototoxic reaction.
Terminal elimination half-life is approximately 2 hours (range 1.1–2.5 h) for trioxsalen after oral administration; clinical phototoxic effect peaks at 2–4 hours post-dose.
Renal excretion of metabolites (~95%) with <0.5% unchanged; biliary/fecal elimination ~5%.
Primarily renal elimination of metabolites; less than 5% excreted unchanged in urine. Approximately 90% of a radiolabeled dose is recovered in urine within 24 hours, with less than 5% in feces.
Category C
Category C
Psoralen
Psoralen